Antibody engineering: Molecular constructor on the basis of barnase-barstar module

Today, antibody engineering for clinical applications is a rapidly progressing field of science and a big business. The basic functions of an antibody can be spatially differentiated and attributed to various structural domains of a molecule. Therefore, each of them may be an object for engineering with the aim of using a definite antibody function. In this sense, the potential of antibodies is unique. In this article, recent achievements and current problems of antibody engineering are briefly reviewed. The main attention is focused on a molecular constructor that allows for obtaining, with the help of a versatile barnase-barstar module, mono- and multivalent miniantibodies and their derivatives with outlined properties.

[1]  André Pèlegrin,et al.  Targeting of Human Breast Cancer by a Bispecific Antibody Directed against Two Tumour-Associated Antigens: ErbB-2 and Carcinoembryonic Antigen , 2002, Tumor Biology.

[2]  Y. Tsybovsky,et al.  Partially structured state of the functional VH domain of the mouse anti‐ferritin antibody F11 , 2002, FEBS letters.

[3]  G. Bastert,et al.  Intraperitoneal bispecific antibody (HEA125xOKT3) therapy inhibits malignant ascites production in advanced ovarian carcinoma , 2002, International journal of cancer.

[4]  Qian Zhang,et al.  Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins , 2004, Nature Biotechnology.

[5]  S. Deyev,et al.  A new vector for controllable expression of an anti-HER2/neu mini-antibody-barnase fusion protein in HEK 293T cells. , 2006, Gene.

[6]  G. A. Lazar,et al.  Engineered antibody Fc variants with enhanced effector function. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[7]  A. Chumanevich,et al.  Antiferritin single‐chain antibody: a functional protein with incomplete folding? , 1998, FEBS letters.

[8]  A. Plückthun,et al.  New protein engineering approaches to multivalent and bispecific antibody fragments. , 1997, Immunotechnology : an international journal of immunological engineering.

[9]  S. Deyev,et al.  Production of recombinant antibodies in lymphoid and non‐lymphoid cells , 1993, FEBS letters.

[10]  L. Ellis,et al.  Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  M. Lieber,et al.  Lymphoid V(D)J recombination: nucleotide insertion at signal joints as well as coding joints. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[12]  C. Contag,et al.  Enhanced Killing of Primary Ovarian Cancer by Retargeting Autologous Cytokine-Induced Killer Cells with Bispecific Antibodies: A Preclinical Study , 2006, Clinical Cancer Research.

[13]  W. Ardelt,et al.  Onconase and amphinase, the antitumor ribonucleases from Rana pipiens oocytes. , 2008, Current pharmaceutical biotechnology.

[14]  Louis M Weiner,et al.  Fully Human Therapeutic Monoclonal Antibodies , 2006, Journal of immunotherapy.

[15]  D. Goldenberg,et al.  Targeted Therapy of Cancer: New Prospects for Antibodies and Immunoconjugates , 2006, CA: a cancer journal for clinicians.

[16]  Y. Yarden,et al.  Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.

[17]  S. Thierfelder,et al.  Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies. , 1995, Journal of immunology.

[18]  S. Muyldermans,et al.  Naturally occurring antibodies devoid of light chains , 1993, Nature.

[19]  Louis M. Weiner,et al.  Building better magic bullets — improving unconjugated monoclonal antibody therapy for cancer , 2007, Nature Reviews Cancer.

[20]  O. Stremovskiy,et al.  Expression of single-chain antibody-barstar fusion in plants. , 2007, Biochimie.

[21]  S. Gambhir,et al.  Quantum Dots for Live Cells, in Vivo Imaging, and Diagnostics , 2005, Science.

[22]  S. G. Odintsov,et al.  Fusion of the antiferritin antibody VL domain to barnase results in enhanced solubility and altered pH stability. , 2004, Protein engineering, design & selection : PEDS.

[23]  K. Lukyanov,et al.  Targeting cancer cells by using an antireceptor antibody-photosensitizer fusion protein , 2009, Proceedings of the National Academy of Sciences.

[24]  S. Rybak,et al.  Targeted therapeutic RNases (ImmunoRNases) , 2009 .

[25]  V. Novikov,et al.  Spin Label Method Reveals Barnase-Barstar Interaction: A Temperature and Viscosity Dependence Approach , 2008, Journal of Biomolecular Structure and Dynamics.

[26]  Sergey M. Deev,et al.  Reciprocal recombination products of VK-JK joining reactions in human lymphoid cell lines , 1987, Nucleic Acids Res..

[27]  S. Deyev,et al.  Expression of immunoglobulin genes tandem in eukaryotic cells under the control of T7 bacteriophage RNA polymerase , 1994, Applied biochemistry and biotechnology.

[28]  T. Hasan,et al.  Strategies for Enhanced Photodynamic Therapy Effects † , 2007, Photochemistry and photobiology.

[29]  S. Iida,et al.  Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies , 2006, Expert opinion on biological therapy.

[30]  I. Benhar.  Design of synthetic antibody libraries , 2007, Expert opinion on biological therapy.

[31]  Andreas Plückthun,et al.  Design of multivalent complexes using the barnase·barstar module , 2003, Nature Biotechnology.

[32]  A. Mirzabekov,et al.  Protein Microchips: Analysis of the Expression of the Recombinant Barstar , 2003, Doklady Biochemistry and Biophysics.

[33]  D. Goldenberg,et al.  Novel designs of multivalent anti-CD20 humanized antibodies as improved lymphoma therapeutics. , 2008, Cancer research.

[34]  Green Nm,et al.  Avidin and streptavidin. , 1990 .

[35]  S. Batra,et al.  Engineering antibodies for clinical applications. , 2007, Trends in biotechnology.

[36]  W. Mcbride,et al.  Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[37]  Shuming Nie,et al.  Single chain epidermal growth factor receptor antibody conjugated nanoparticles for in vivo tumor targeting and imaging. , 2008, Small.

[38]  Ilya V Turchin,et al.  Fluorescent immunolabeling of cancer cells by quantum dots and antibody scFv fragment. , 2009, Journal of biomedical optics.

[39]  Sergey M Deyev,et al.  Multivalency: the hallmark of antibodies used for optimization of tumor targeting by design. , 2008, BioEssays : news and reviews in molecular, cellular and developmental biology.

[40]  R. Raines,et al.  Evasion of ribonuclease inhibitor as a determinant of ribonuclease cytotoxicity. , 2008, Current pharmaceutical biotechnology.

[41]  R. Kontermann.  Recombinant bispecific antibodies for cancer therapy , 2005, Acta Pharmacologica Sinica.

[42]  W. Mcbride,et al.  Improving the Delivery of Radionuclides for Imaging and Therapy of Cancer Using Pretargeting Methods , 2005, Clinical Cancer Research.

[43]  M. Deonarain.  Recombinant antibodies for cancer therapy , 2008, Expert opinion on biological therapy.

[44]  G. V. Lutsenko,et al.  Barnase as a New Therapeutic Agent Triggering Apoptosis in Human Cancer Cells , 2008, PloS one.

[45]  S. Deyev,et al.  Cloning of an alkaline phosphatase gene from the moderately thermophilic bacterium Meiothermus ruber and characterization of the recombinant enzyme , 2003, Molecular Genetics and Genomics.

[46]  Leonard G. Presta,et al.  High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγR* , 2001, The Journal of Biological Chemistry.

[47]  G. Schreiber.  Methods for studying the interaction of barnase with its inhibitor barstar. , 2001, Methods in molecular biology.

[48]  Michaela A. E. Arndt,et al.  Efficient killing of CD22+ tumor cells by a humanized diabody-RNase fusion protein. , 2005, Biochemical and biophysical research communications.

[49]  Noreen R. Gonzales,et al.  SDR grafting--a new approach to antibody humanization. , 2005, Methods.

[50]  L. Riel.  Table of Contents , 2010, Biological Psychiatry.

[51]  S. Batra,et al.  Penetratin improves tumor retention of single-chain antibodies: a novel step toward optimization of radioimmunotherapy of solid tumors. , 2005, Cancer research.

[52]  Randall J. Lee,et al.  Antibody Targeting of Stem Cells to Infarcted Myocardium , 2007, Stem cells.

[53]  A. Plückthun,et al.  Stability engineering of antibody single-chain Fv fragments. , 2001, Journal of molecular biology.

[54]  Konstantin A Lukyanov,et al.  A genetically encoded photosensitizer , 2006, Nature Biotechnology.

[55]  C. Milstein,et al.  Continuous cultures of fused cells secreting antibody of predefined specificity , 1975, Nature.

[56]  R. Kiessling,et al.  Her-2/neu as a paradigm of a tumor-specific target for therapy. , 2004, Breast disease.

[57]  R. Ivkov,et al.  NanoFerrite particle based radioimmunonanoparticles: binding affinity and in vivo pharmacokinetics. , 2008, Bioconjugate chemistry.

[58]  H. Koeppen,et al.  Identification and immunotherapeutic targeting of antigens induced by chemotherapy , 2006, Nature Biotechnology.

[59]  P. Kufer,et al.  BiTE: Teaching antibodies to engage T-cells for cancer therapy. , 2009, Current opinion in molecular therapeutics.

[60]  L. Weiner,et al.  Antibody constructs in cancer therapy , 2007, Cancer.

[61]  O. Stremovskiy,et al.  Production of recombinant antitumor antibodies by HEK-293 cells , 2006, Doklady Biochemistry and Biophysics.

[62]  A. Makarov,et al.  Binase and other microbial RNases as potential anticancer agents. , 2008, BioEssays : news and reviews in molecular, cellular and developmental biology.

[63]  V. Orekhov,et al.  NMR study of monomer-dimer equilibrium of barstar in solution. , 2001, Journal of the American Chemical Society.

[64]  R. Hartley,et al.  Ribonuclease-charged vector for facile direct cloning with positive selection , 1998, Molecular and General Genetics MGG.

[65]  R. Hartley.  Barnase-barstar interaction. , 2001, Methods in enzymology.

[66]  G. Adams,et al.  Monoclonal antibody therapy of cancer , 1999, Nature Biotechnology.

[67]  S. Deyev,et al.  Expression of the chimeric IgE gene in cell culture and in various mouse tissues. , 2004, Biochimie.

[68]  F. Crozet,et al.  Method for generation of human hyperdiversified antibody fragment library , 2007, Biotechnology journal.

[69]  H. Hoogenboom,et al.  Selecting and screening recombinant antibody libraries , 2005, Nature Biotechnology.

[70]  I. V. Orlova,et al.  Biosynthesis of the scFv Antibody to Human Ferritin in Plant and Bacterial Producers , 2003, Molecular Biology.

[71]  G. D'alessio,et al.  From immunotoxins to immunoRNases. , 2008, Current pharmaceutical biotechnology.

[72]  L. Vinokurov,et al.  Barnase-barstar high affinity interaction phenomenon as the base for the heterogenous bioluminescence pseudorabies virus' immunoassay. , 2007, Journal of biochemical and biophysical methods.

[73]  L. Presta,et al.  'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. , 1996, Protein engineering.

[74]  Y. Tsybovsky,et al.  Antiferritin single-chain Fv fragment is a functional protein with properties of a partially structured state: comparison with the completely folded V(L) domain. , 2000, Biochemistry.

[75]  Shigeru Iida,et al.  Establishment of FUT8 knockout Chinese hamster ovary cells: An ideal host cell line for producing completely defucosylated antibodies with enhanced antibody‐dependent cellular cytotoxicity , 2004, Biotechnology and bioengineering.

[76]  Anna M Wu,et al.  Arming antibodies: prospects and challenges for immunoconjugates , 2005, Nature Biotechnology.

[77]  W. Weng,et al.  Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  P. Hudson,et al.  Engineered antibody fragments and the rise of single domains , 2005, Nature Biotechnology.

[79]  A. Fersht,et al.  Protein-protein recognition: crystal structural analysis of a barnase-barstar complex at 2.0-A resolution. , 1994, Biochemistry.

[80]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[81]  S. Deyev,et al.  A new phagemid vector for positive selection of recombinants based on a conditionally lethal barnase gene , 1999, FEBS Letters.

[82]  Nathan C Shaner,et al.  A guide to choosing fluorescent proteins , 2005, Nature Methods.

[83]  R. Hartley,et al.  A plasmid vector with positive selection and directional cloning based on a conditionally lethal gene. , 1996, Gene.

[84]  S. Deyev,et al.  The quantitative characteristics of efficiency of ballistic transfection of chimeric antibody genes. , 2000, Immunology letters.

[85]  T. Wurch,et al.  Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins. , 2008, Current pharmaceutical biotechnology.

[86]  P. Bohlen,et al.  Simultaneous Blockade of Both the Epidermal Growth Factor Receptor and the Insulin-like Growth Factor Receptor Signaling Pathways in Cancer Cells with a Fully Human Recombinant Bispecific Antibody* , 2004, Journal of Biological Chemistry.

[87]  K. D. Hardman,et al.  Single-chain antigen-binding proteins. , 1988, Science.

[88]  O. Boerman,et al.  Cancer Imaging and Therapy with Bispecific Antibody Pretargeting. , 2007, Update on cancer therapeutics.